Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Two Antibiotics To Treat C. Difficile

by Alex Scott
June 16, 2014 | A version of this story appeared in Volume 92, Issue 24

Synthetic Biologics has joined with French biotech firm Enterome Bioscience to test β-lactam antibiotics in the presence of Synthetic Biologics’ drug candidate ­SYN-004 for the treatment of Clostridium difficile, a hard-to-treat bacterium that can infect the human gut, causing colitis (see page 9). The firms plan to begin testing the combination in a Phase I trial on 100 patients beginning next month. Separately, Glasgow, Scotland-based MGB Biopharma has been awarded $2.2 million from the Technology Strategy Board, a U.K. government agency, to fund Phase I trials for MGB-BP-3, its drug candidate for treating C. difficile. MGB plans to begin trials by early 2015.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.